The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families
Open accessAbstract
Pathogenic mutations in APP, PSEN1, PSEN2, MAPT and GRN have previously been linked to familial early onset forms of dementia. Mutation screening in these genes has been performed in either very small series or in single families with late onset AD (LOAD). Similarly, studies in single families have reported mutations in MAPT and GRN associated with clinical AD but no systematic screen of a large dataset has been performed to determine how frequently this occurs. We report sequence data for 439 probands from late-onset AD families with a history of four or more affected individuals. Sixty sequenced individuals (13.7%) carried a novel or pathogenic mutation. Eight pathogenic variants, (one each in APP and MAPT, two in PSEN1 and four in GRN) three of which are novel, were found in 14 samples. Thirteen additional variants, present in 23 families, did not segregate with disease, but the frequency of these variants is higher in AD cases than controls, indicating that these variants may also modify risk for disease. The frequency of rare variants in these genes in this series is significantly higher than in the 1,000 genome project (p = 5.09 × 10⁻⁵; OR = 2.21; 95%CI = 1.49-3.28) or an unselected population of 12,481 samples (p = 6.82 × 10⁻⁵; OR = 2.19; 95%CI = 1.347-3.26). Rare coding variants in APP, PSEN1 and PSEN2, increase risk for or cause late onset AD. The presence of variants in these genes in LOAD and early-onset AD demonstrates that factors other than the mutation can impact the age at onset and penetrance of at least some variants associated with AD. MAPT and GRN mutations can be found in clinical series of AD most likely due to misdiagnosis. This study clearly demonstrates that rare variants in these genes could explain an important proportion of genetic heritability of AD, which is not detected by GWAS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“suggesting that rare variants in genes associated with AD pathogenesis could explain a significant proportion of genetic heritability of AD, which is not detected by genomewide association studies (53)”
From Molecular Basis for Increased Risk for Late-onset Alzheimer Disease Due to the Naturally Occurring L28P Mutation in Apolipoprotein E4 (2014) · cites this paper as [53]
The cited source says what the claim attributes to it.
In the citing paper
“A characteristic example involves a mutation screening study that showed that rare variants in amyloid  precursor protein, presenilin 1, and presenilin 2 increased the risk for AD in LOAD families, suggesting that rare variants in genes associated with AD pathogenesis could explain a significant proportion of genetic heritability of AD, which is not detected by genomewide association studies (53)”
From Molecular Basis for Increased Risk for Late-onset Alzheimer Disease Due to the Naturally Occurring L28P Mutation in Apolipoprotein E4 (2014) · cites this paper as [53]
In the citing paper
“In support, sequencing studies have identified rare variants in APP, PSEN1, and PSEN2 that increase risk for LOAD [157].”
From Genetic architecture of Alzheimer's disease (2020) · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
A method and server for predicting damaging missense mutations.
Adzhubei, I. A., Schmidt, S., Peshkin, L., Ramensky, V. E., Gerasimova, A., Bork, P., Kondrashov, A. S., & Sunyaev, S. R. (2010) · Nature Methods · doi:10.1038/nmeth0410-248 · Cited by 13,194
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationHarold, D., Abraham, R., Hollingworth, P., Sims, R., Gerrish, A., Hamshere, M. L., Pahwa, J. S., Moskvina, V., Dowzell, K., Williams, A., et al. (2009) · Nature Genetics · doi:10.1038/ng.440 · Cited by 3,326
Self-citationGenome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease
the European Alzheimer's Disease Initiative Investigators, Lambert, J.-C., Heath, S., Even, G., Campion, D., Sleegers, K., Hiltunen, M., Combarros, O., Zelenika, D., Bullido, M. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.439 · Cited by 2,234
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Self-citationNaj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Self-citationRole of Genes and Environments for Explaining Alzheimer Disease
Gatz, M., Reynolds, C. A., Fratiglioni, L., Johansson, B., Mortimer, J. A., Berg, S., Fiske, A., & Pedersen, N. L. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.2.168 · Cited by 1,798
The Clinical Diagnosis of Alzheimer's Disease
Wade, J. P. H., Mirsen, T. R., Hachinski, V. C., Fisman, M., Lau, C. S., & Merskey, H. (1987) · Archives of Neurology · doi:10.1001/archneur.1987.00520130016010 · Cited by 1,416
Genome-wide Analysis of Genetic Loci Associated With Alzheimer Disease
Seshadri, S. (2010) · JAMA · doi:10.1001/jama.2010.574 · Cited by 1,219
Cited by
Sorted by citations
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Alzheimer’s Disease Risk Genes and Mechanisms of Disease Pathogenesis
Karch, C. M., & Goate, A. M. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.05.006 · Cited by 1,357
Self-citationCooper, D. N., Krawczak, M., Polychronakos, C., Tyler‐Smith, C., & Kehrer‐Sawatzki, H. (2013) · Human Genetics · doi:10.1007/s00439-013-1331-2 · Cited by 671
Molecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617
Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002270 · Cited by 616
Arendt, T., Stieler, J. T., & Holzer, M. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.08.018 · Cited by 609
Alzheimer’s Disease Genetics: From the Bench to the Clinic
Karch, C. M., Cruchaga, C., & Goate, A. M. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.041 · Cited by 473
Self-citationRare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Cruchaga, C., Karch, C. M., Jin, S. C., Benitez, B. A., Cai, Y., Guerreiro, R., Harari, O., Norton, J., Budde, J., Bertelsen, S., et al. (2014) · Nature · doi:10.1038/nature12825 · Cited by 461
Self-citationSantos, C. Y., Snyder, P. J., Wu, W., Zhang, M., Echeverria, A., & Alber, J. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.01.005 · Cited by 431
Regional variability of imaging biomarkers in autosomal dominant Alzheimer's disease
Benzinger, T. L. S., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., Raichle, M. E., Snyder, A. Z., Ances, B. M., Bateman, R. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317918110 · Cited by 391
Self-citationLoy, C. T., Schofield, P. R., Turner, A. M., & Kwok, J. B. (2014) · The Lancet · doi:10.1016/s0140-6736(13)60630-3 · Cited by 342
Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Piccio, L., Deming, Y., Del-Águila, J. L., Ghezzi, L., Holtzman, D. M., Fagan, A. M., Fenoglio, C., Galimberti, D., Borroni, B., & Cruchaga, C. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1533-5 · Cited by 337
Self-citationCoding variants in TREM2 increase risk for Alzheimer's disease
Jin, S. C., Benitez, B. A., Karch, C. M., Cooper, B., Skorupa, T., Carrell, D., Norton, J. B., Hsu, S., Harari, O., Cai, Y., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu277 · Cited by 314
Self-citationLewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
Clearance of cerebral Aβ in Alzheimer’s disease: reassessing the role of microglia and monocytes
Zuroff, L. R., Daley, D. A., Black, K. L., & Koronyo‐Hamaoui, M. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2463-7 · Cited by 292
Risk prediction of late-onset Alzheimer’s disease implies an oligogenic architecture
Zhang, Q., Sidorenko, J., Couvy-Duchesne, B., Marioni, R. E., Wright, M. J., Goate, A. M., Marcora, E., Huang, K.-L., Porter, T., Laws, S. M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18534-1 · Cited by 272
Self-citationTREM2and Neurodegenerative Disease
Reitz, C., & Mayeux, R. P. (2013) · New England Journal of Medicine · doi:10.1056/nejmc1306509 · Cited by 258
Self-citationIncreased in Vivo Amyloid-β42 Production, Exchange, and Loss in Presenilin Mutation Carriers
Potter, R., Patterson, B. W., Elbert, D. L., Ovod, V., Kasten, T., Sigurdson, W., Mawuenyega, K., Blazey, T., Goate, A., Chott, R., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005615 · Cited by 236
Self-citationMarzi, S. J., Leung, S. K., Ribarska, T., Hannon, E., Smith, A. R., Pishva, E., Poschmann, J., Moore, K., Troakes, C., Al-Sarraj, S., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0253-7 · Cited by 232
Mullane, K., & Williams, M. J. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.11.014 · Cited by 219
Genetics of Alzheimer’s Disease
Chouraki, V. A., & Seshadri, S. S. (2014) · Advances in genetics · doi:10.1016/b978-0-12-800149-3.00005-6 · Cited by 220
Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease
Cruchaga, C., Kauwe, J. S. K., Nowotny, P., Bales, K., Pickering, E. H., Mayo, K., Bertelsen, S., Hinrichs, A., Fagan, A. M., Holtzman, D. M., et al. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds296 · Cited by 207
Self-citationMaloney, J. A., Bainbridge, T. W., Gustafson, A. E., Zhang, S., Kyauk, R. V., Steiner, P., van der Brug, M., Liu, Y., Ernst, J. A., Watts, R. J., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.589069 · Cited by 211
Developmental trajectories as autism phenotypes
Lord, C., Bishop, S. L., & Anderson, D. K. (2015) · American Journal of Medical Genetics Part C Seminars in Medical Genetics · doi:10.1002/ajmg.c.31440 · Cited by 210
Pathways to Alzheimer's disease
Hardy, J., Bogdanović, N., Winblad, B. G., Portelius, E., Andreasen, N. C., Cedazo-Mínguez, Á., & Zetterberg, H. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12192 · Cited by 180
Recent Progress in Alzheimer’s Disease Research, Part 2: Genetics and Epidemiology
Robinson, M. J., Lee, B. Y., & Hane, F. T. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161149 · Cited by 179
TREM2 is associated with the risk of Alzheimer's disease in Spanish population
Benitez, B. A., Cooper, B., Pastor, P., Jin, S.-C., Lorenzo, E., Cervantes, S., & Cruchaga, C. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.018 · Cited by 163
Self-citationA global view of the genetic basis of Alzheimer disease
Reitz, C., Pericak‐Vance, M. A., Foroud, T., & Mayeux, R. P. (2023) · Nature Reviews Neurology · doi:10.1038/s41582-023-00789-z · Cited by 181
Self-citationPark, J. S., Lee, J., Jung, E. S., Kim, M.-H., Kim, I. B., Son, H., Kim, S., Kim, S., Park, Y. M., Mook-Jung, I., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11000-7 · Cited by 155
McKenzie, A. T., Moyon, S., Wang, M., Katsyv, I., Song, W.-M., Zhou, X., Dammer, E. B., Duong, D. M., Aaker, J., Zhao, Y., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0219-3 · Cited by 154
Alzheimer's Disease Genetics Consortium, Wetzel-Smith, M. K., Hunkapiller, J., Bhangale, T. R., Srinivasan, K., Maloney, J. A., Atwal, J. K., Sa, S. M., B Yaylaoglu, M., Foreman, O., et al. (2014) · Nature Medicine · doi:10.1038/nm.3736 · Cited by 153
Self-citationDissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
Whole‐exome sequencing in 20,197 persons for rare variants in Alzheimer's disease
Raghavan, N. S., Brickman, A. M., Andrews, H., Manly, J. J., Schupf, N., Lantigua, R., Wolock, C. J., Kamalakaran, S., Petrovski, S., Tosto, G., et al. (2018) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.582 · Cited by 141
Self-citationCruchaga, C., Del‐Aguila, J. L., Saef, B., Black, K., Fernandez, M. V., Budde, J., Ibanez, L., Deming, Y., Kapoor, M., Tosto, G., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.08.013 · Cited by 138
Self-citationProtective genes and pathways in Alzheimer’s disease: moving towards precision interventions
Seto, M., Weiner, R. L., Dumitrescu, L., & Hohman, T. J. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00452-5 · Cited by 135
Genetics of Alzheimer’s Disease
Vilatela, M. E. A., López, M., & Yescas, P. (2012) · Archives of Medical Research · doi:10.1016/j.arcmed.2012.10.017 · Cited by 138
Genetic analyses of early-onset Alzheimer’s disease using next generation sequencing
Giau, V. V., Bagyinszky, E., Yang, Y. S., Youn, Y. C., An, S. S. A., & Kim, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-44848-2 · Cited by 137
Genetic architecture of Alzheimer's disease
Neuner, S. M., TCW, J., & Goate, A. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104976 · Cited by 126
“Given the overlap between EOAD and LOAD as discussed above, these modifiers may provide potential therapeutic targets for a more general population.”
BackgroundInfluentialSelf-citationTang, M., Ryman, D. C., McDade, E., Jasielec, M. S., Buckles, V. D., Cairns, N. J., Fagan, A. M., Goate, A., Marcus, D. S., Xiong, C., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30229-0 · Cited by 121
Self-citationGenetic diagnosis and prognosis of Alzheimer’s disease: challenges and opportunities
Reitz, C. (2015) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2015.1002469 · Cited by 125
Genetics, Functions, and Clinical Impact of Presenilin-1 (PSEN1) Gene
Bagaria, J., Bagyinszky, E., & An, S. S. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810970 · Cited by 125
Local ancestry at APOE modifies Alzheimer's disease risk in Caribbean Hispanics
Blue, E., Horimoto, A. R. V. R., Mukherjee, S., Wijsman, E. M., & Thornton, T. A. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.07.016 · Cited by 113
Genetics of neurodegenerative diseases: an overview
Pihlstrøm, L., Wiethoff, S., & Houlden, H. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00022-5 · Cited by 120
Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells
Libro, R., Diomede, F., Scionti, D., Piattelli, A., Grassi, G., Pollastro, F., Bramanti, P., Mazzon, E., & Trubiani, O. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010026 · Cited by 110
Suárez‐Calvet, M., Capell, A., Araque Caballero, M. Á., Morenas‐Rodríguez, E., Fellerer, K., Franzmeier, N., Kleinberger, G., Eren, E., Deming, Y., Piccio, L., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809712 · Cited by 109
Self-citationEpigenetic regulation in neurodevelopment and neurodegenerative diseases
Gapp, K., Woldemichael, B. T., Bohacek, J., & Mansuy, I. M. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.11.040 · Cited by 110
Jin, S. C., Pástor, P., Cooper, B., Cervantes, S., Benítez, B. A., Razquín, C., Goate, A., Ibero-American Alzheimer Disease Genetics Group Researchers, & Cruchaga, C. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt137 · Cited by 106
Self-citationC9orf72 Hexanucleotide Repeat Expansions in Clinical Alzheimer Disease
Harms, M., Benitez, B. A., Cairns, N., Cooper, B., Cooper, P., Mayo, K., Carrell, D., Faber, K., Williamson, J., Bird, T., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.537 · Cited by 102
Self-citationVariants in GBA , SNCA , and MAPT influence Parkinson disease risk, age at onset, and progression
Davis, A. A., Andruska, K. M., Benítez, B. A., Racette, B. A., Perlmutter, J. S., & Cruchaga, C. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.09.014 · Cited by 107
Self-citationAn, S. S. A., Cai, Y., & Kim, S. (2015) · Clinical Interventions in Aging · doi:10.2147/cia.s85808 · Cited by 112
The role of large pedigrees in an era of high-throughput sequencing
Wijsman, E. M. (2012) · Human Genetics · doi:10.1007/s00439-012-1190-2 · Cited by 99
Toward precision medicine in Alzheimer’s disease
Reitz, C. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.03.05 · Cited by 100
Thomas, A. L., Lehn, M. A., Janssen, E. M., Hildeman, D. A., & Chougnet, C. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-21920-y · Cited by 94
Rathore, N., Ramani, S. R., Pantua, H., Payandeh, J., Bhangale, T., Wuster, A., Kapoor, M., Sun, Y., Kapadia, S. B., Gonzalez, L., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007427 · Cited by 93
Self-citationPoey, J. L., Burr, J. A., & Roberts, J. S. (2017) · The Gerontologist · doi:10.1093/geront/gnw154 · Cited by 99
The missing link in the amyloid cascade of Alzheimer’s disease – Metal ions
Tiiman, A., Palumaa, P., & Tõugu, V. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.01.023 · Cited by 92
The Patterns of Inheritance in Early-Onset Dementia
Jarmolowicz, A. I., Chen, H.-Y., & Panegyres, P. K. (2014) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317514545825 · Cited by 91
Inflammation in Alzheimer’s Disease and Molecular Genetics: Recent Update
Zhang, Z., Li, Y., Ng, C. T., & Song, Y. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0351-0 · Cited by 92
Repeat expansions in the C9ORF72 gene contribute to Alzheimer's disease in Caucasians
Kohli, M. A., John‐Williams, K., Rajbhandary, R., Naj, A. C., Whitehead, P. L., Hamilton, K., Carney, R. M., Wright, C. B., Crocco, E., Gwirtzman, H. E., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.003 · Cited by 83
Alzheimer’s disease: as it was in the beginning
Kozlov, S. O., Afonin, A. М., Evsyukov, I., & Бондаренко, А. Б. (2017) · Reviews in the Neurosciences · doi:10.1515/revneuro-2017-0006 · Cited by 87
Kodam, P., Sai Swaroop, R., Pradhan, S. S., Sivaramakrishnan, V., & Vadrevu, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-30892-6 · Cited by 82
Kara, E., Ling, H., Pittman, A. M., Shaw, K., de Silva, R., Simone, R., Holton, J. L., Warren, J. D., Rohrer, J. D., Xiromerisiou, G., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.04.006 · Cited by 81
Early Life Stress and Epigenetics in Late-onset Alzheimer’s Dementia: A Systematic Review
Lemche, E. (2018) · Current Genomics · doi:10.2174/1389202919666171229145156 · Cited by 84
PSEN1, PSEN2, and APP mutations in 404 Chinese pedigrees with familial Alzheimer's disease
Jia, L., Fu, Y., Shen, L., Zhang, H., Zhu, M., Qiu, Q., Wang, Q., Yan, X., Kong, C., Hao, J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12005 · Cited by 82
Harms, M. B., Cady, J., Zaidman, C. M., Cooper, P., Bali, T., Allred, P., Cruchaga, C., Baughn, M. W., Libby, R. T., Pestronk, A., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.006 · Cited by 76
Self-citationParkinson’s Disease is Predominantly a Genetic Disease
Lim, S., & Klein, C. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-230376 · Cited by 75
The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
Freudenberg‐Hua, Y., Li, W., & Davies, P. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00108 · Cited by 80
Vardarajan, B. N., Faber, K. M., Bird, T. D., Bennett, D. A., Rosenberg, R., Boeve, B. F., Graff-Radford, N. R., Goate, A. M., Farlow, M., Sweet, R. A., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5570 · Cited by 73
Self-citationUnderstanding the cause of sporadic Alzheimer’s disease
Zetterberg, H., & Mattsson, N. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.915740 · Cited by 73
Genomics and Functional Genomics of Alzheimer's Disease
Kamboh, M. I. (2022) · Neurotherapeutics · doi:10.1007/s13311-021-01152-0 · Cited by 73
Sala Frigerio, C., Lau, P., Troakes, C., Deramecourt, V., Gele, P., Van Loo, P., Voet, T., & De Strooper, B. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.007 · Cited by 71
Exploring the Role of PSEN Mutations in the Pathogenesis of Alzheimer’s Disease
Kabir, M. T., Uddin, M. S., Setu, J. R., Ashraf, G. M., Bin-Jumah, M. N., & Abdel‐Daim, M. M. (2020) · Neurotoxicity Research · doi:10.1007/s12640-020-00232-x · Cited by 72
Translational approaches to understanding resilience to Alzheimer’s disease
Neuner, S. M., Telpoukhovskaia, M., Menon, V., O’Connell, K. M. S., Hohman, T. J., & Kaczorowski, C. C. (2022) · Trends in Neurosciences · doi:10.1016/j.tins.2022.02.005 · Cited by 68
Sassi, C., Guerreiro, R. J., Gibbs, J. R., Ding, J., Lupton, M. K., Troakes, C., Al‐Sarraj, S., Niblock, M., Gallo, J., Adnan, J., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.002 · Cited by 68
Analysis of 50 Neurodegenerative Genes in Clinically Diagnosed Early-Onset Alzheimer’s Disease
Giau, V. V., Senanarong, V., Bagyinszky, E., An, S. S. A., & Kim, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061514 · Cited by 64
Halloran, M. A., Parakh, S., & Atkin, J. D. (2013) · International Journal of Cell Biology · doi:10.1155/2013/797914 · Cited by 65
The PSEN1, p.E318G Variant Increases the Risk of Alzheimer's Disease in APOE-ε4 Carriers
Benítez, B. A., Karch, C. M. M., Cai, Y., Jin, S. C., Cooper, B., Carrell, D., Bertelsen, S. E., Chibnik, L. B., Schneider, J. A., Bennett, D., et al. (2013) · PLoS Genetics · doi:10.1371/journal.pgen.1003685 · Cited by 68
Self-citationAmyloid-beta immunotherapy: the hope for Alzheimer disease?
Barrera-Ocampo, A. A., & Lopera, F. J. (2016) · Colombia medica · doi:10.25100/cm.v47i4.2640 · Cited by 64
A network approach to clinical intervention in neurodegenerative diseases
Santiago, J. A., & Potashkin, J. A. (2014) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.002 · Cited by 62
Early-Onset Alzheimer Disease and Candidate Risk Genes Involved in Endolysosomal Transport
Kunkle, B. W., Vardarajan, B. N., Naj, A. C., Whitehead, P. L., Rolati, S., Slifer, S., Carney, R. M., Cuccaro, M. L., Vance, J. M., Gilbert, J. R., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1518 · Cited by 58
Self-citationPresenilin 2 influences miR146 level and activity in microglia
Jayadev, S., Case, A., Alajajian, B., Eastman, A. J., Möller, T., & Garden, G. A. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12400 · Cited by 62
TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT
Ling, H., Kara, E., Bandopadhyay, R., Hardy, J., Holton, J. L., Xiromerisiou, G., Lees, A. J., Houlden, H., & Révész, T. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.04.011 · Cited by 60
Rossi, G., & Tagliavini, F. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00192 · Cited by 62
Clinical Trials in Predementia Stages of Alzheimer Disease
Pillai, J. A., & Cummings, J. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2013.01.002 · Cited by 58
Guerreiro, R. J., Brás, J., Hardy, J., & Singleton, A. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu203 · Cited by 54
Kallop, D. Y., Meilandt, W. J., Gogineni, A., Easley-Neal, C., Wu, T., Jubb, A. M., Yaylaoglu, M., Shamloo, M., Tessier-Lavigne, M., Scearce-Levie, K., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.4963-13.2014 · Cited by 54
Curcumin: a natural substance with potential efficacy in Alzheimer’s disease
Potter, P. E. (2013) · Journal of Experimental Pharmacology · doi:10.2147/jep.s26803 · Cited by 51
Alzheimer Disease: Perspectives from Epidemiology and Genetics
Haines, J. L. (2018) · The Journal of Law Medicine & Ethics · doi:10.1177/1073110518804230 · Cited by 51
Characterization of the chromatin accessibility in an Alzheimer’s disease (AD) mouse model
Wang, Y., Zhang, X., Song, Q., Hou, Y., Liu, J., Sun, Y., & Wang, P. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00598-2 · Cited by 51
Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2
Hsu, S., Pimenova, A. A., Hayes, K., Villa, J. A., Rosene, M. J., Jere, M., Goate, A., & Karch, C. M. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104817 · Cited by 45
Self-citationTREM2 expression and amyloid‐beta phagocytosis in Alzheimer's disease
La Rosa, F., Agostini, S., Piancone, F., Marventano, I., Hernis, A., Fenoglio, C., Galimberti, D., Scarpini, E., Saresella, M., & Clerici, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108626 · Cited by 50
Rarity of the Alzheimer Disease–ProtectiveAPPA673T Variant in the United States
Wang, L.-S., Naj, A. C., Graham, R., Crane, P. K., Kunkle, B. W., Cruchaga, C., Murcia, J. D. G., Cannon‐Albright, L., Baldwin, C. T., Zetterberg, H., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.2157 · Cited by 47
Self-citationFrom beta amyloid to altered proteostasis in Alzheimer’s disease
Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 47
Alternative splicing in a presenilin 2 variant associated with Alzheimer disease
Braggin, J. E., Bucks, S. A., Course, M. M., Smith, C., Sopher, B. L., Osnis, L., Shuey, K. D., Domoto‐Reilly, K., Caso, C., Kinoshita, C., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.755 · Cited by 46
Self-citationNetCore: a network propagation approach using node coreness
Barel, G., & Herwig, R. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa639 · Cited by 46
Alzheimer’s Disease: From Genetic Variants to the Distinct Pathological Mechanisms
Sun, Q., Xie, N., Tang, B., Li, R., & Shen, Y. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00319 · Cited by 46
Alzheimer’s as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks
Castrillo, J. I., & Oliver, S. G. (2016) · Methods in Molecular Biology · doi:10.1007/978-1-4939-2627-5_1 · Cited by 44
McKay, N. S., Gordon, B. A., Hornbeck, R. C., Dincer, A., Flores, S. E., Keefe, S., Joseph‐Mathurin, N., Jack, C. R., Koeppe, R. A., Millar, P. R., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01359-8 · Cited by 44
Self-citationDisease‐related mutations among Caribbean Hispanics with familial dementia
Lee, J. H., Kahn, A., Cheng, R., Reitz, C., Vardarajan, B. N., Lantigua, R., Medrano, M. Z., Jiménez‐Velázquez, I. Z., Williamson, J., Nagy, P. L., et al. (2014) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.85 · Cited by 43
Self-citation
Metadata
- Authors
- Cruchaga, C., Chakraverty, S., Mayo, K., Vallania, F. L. M., Mitra, R. D., Faber, K., Williamson, J., Bird, T., Diaz-Arrastia, R., Foroud, T. M., Boeve, B. F., Graff-Radford, N. R., St. Jean, P., Lawson, M., Ehm, M. G., Mayeux, R., Goate, A. M., & for the NIA-LOAD/NCRAD Family Study Consortium
- Affiliations
- Washington University in St. Louis (US)
- Indiana University Indianapolis (US)
- Columbia University (US)
- University of Washington (US)
- The University of Texas Southwestern Medical Center (US)
- Mayo Clinic (US)
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Cruchaga, Carlos
- Goate, Alison M.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-02-01
- Volume
- 7
- Issue
- 2
- Pages
- e31039
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3270040
- OpenAlex
- W2023381648
- Cited by
- 320
- References
- 66
- Citations by year
- 2026: 15 · 2025: 14 · 2024: 23 · 2023: 12 · 2022: 20 · 2021: 25 · 2020: 25 · 2019: 10 · 2018: 22 · 2017: 28 · 2016: 26 · 2015: 22 · 2014: 29 · 2013: 32 · 2012: 17
- FWCI
- 21.43
- Type
- journal article
- Language
- en
- Update notices
- correction (2012-05-10)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Veterans Affairs
- Massachusetts General Hospital
- University of Southern California
- University of Pennsylvania (U24 AG026395)
- Northwestern University
- Foundation for Barnes-Jewish Hospital
- University of Washington
- University of Pittsburgh
- Rush University
- National Institutes of Health (5p30ns069329-02, 5r37ag015473-15)
- University of California, Los Angeles
- National Institute on Aging (AG 16208, R37AG15473, R37-AG015473, AG21886, R01AG035083, U24 AG21886, P 50 AG05681, R01AG041797, P50AG008702, P50AG005681, P01 AG0 3991, P01AG003991, AG035083, U24AG026395, P30AG013846, R01AG016208, AG026395, U24AG056270, P01AG026276, U24AG021886)
- National Institute of Mental Health (R01MH060009)
- National Institute of Neurological Disorders and Stroke (P30-NS069329, 1P30NS069329-01)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- late-onset Alzheimer's disease, familial Alzheimer's disease, rare variants, APP, presenilin 1, presenilin 2, MAPT, gene regulatory networks, pathogenic variants, genetic risk, heritability, novel variants, age of onset, penetrance, misdiagnosis, mutation detection
- MeSH terms
- Progranulins, Adult, Aged, Aged, 80 and over, Alzheimer Disease, Female, Humans, Male, Middle Aged, Mutation, Pedigree, Amyloid beta-Protein Precursor, tau Proteins, Genetic Predisposition to Disease, Intercellular Signaling Peptides and Proteins, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
